MiMedx Group, Inc. (MDXG) Guidance & Earnings Results
On 2026-07-29 MiMedx Group, Inc. reaffirmed guidance: "FY26 net sales $260-290M; FY26 Adjusted EBITDA approaching…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MDXGMiMedx Group, Inc.Follow MDXG — free
—
Price chart with a free account
- Market cap
- 569.9M
- P/E TTM
- 97.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Reaffirmed | FY26 net sales $260-290M; FY26 Adjusted EBITDA approaching breakeven · full year |
| 29 Apr 26 | Lowered | FY2026 net sales lowered to $260-290M from prior expectations; FY2026 adjusted EBITDA ~breakeven · full year |
| 25 Feb 26 | Raised | FY2026 net sales guidance $340-360M (6-12% growth) |
| 29 Oct 25 | Raised | Net sales growth raised to mid-to-high teens; adjusted EBITDA margin raised to at least mid-20% · full year |
| 30 Jul 25 | Raised | FY2025 net sales growth low double-digits (previously not specified); FY2025 Adjusted EBITDA margin above 20% · full year |
MiMedx Group, Inc. — questions
- What guidance did MiMedx Group, Inc. give?
- On 2026-07-29: "FY26 net sales $260-290M; FY26 Adjusted EBITDA approaching breakeven"
- When does MiMedx Group, Inc. report earnings?
- MiMedx Group, Inc.'s next earnings report is expected on 2026-10-28.
Every figure on this page comes from MiMedx Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.